Skip to main content
Premium Trial:

Request an Annual Quote

Incyte Strikes Deals with Schering-Plough, Pfizer; Licenses Patented Tech

Premium

PALO ALTO, Calif.--Incyte Pharmaceuticals announced a broad genomic data collaboration that provides Schering-Plough with access to Incyte's microarray technology and databases. Incyte will provide Plough with data from custom and prefabricated DNA microarrays in exchange for technology access and per-array fees. The multiyear collaboration also provides Plough with access to Incyte's LifeSeq gene sequence and expression database and the LifeSeq FL database of full-length genes. Financial terms of the agreement were not disclosed.

Separately, expanding upon an existing relationship, Incyte granted Pfizer a license to its LifeTools bioinformatics software and LifeArray microarray data analysis and management software.

Incyte also announced that it has been granted an exclusive license to what it called a "pioneering gene expression analysis technology" from the Montefiore Medical Center. The technology uses a defined hybridization array to analyze gene expressions useful in diagnosing disease. The method can also be used to evaluate potential risk for disease and monitor the effects of drugs on gene expression, according to Incyte.

Filed under

The Scan

New Study Highlights Role of Genetics in ADHD

Researchers report in Nature Genetics on differences in genetic architecture between ADHD affecting children versus ADHD that persists into adulthood or is diagnosed in adults.

Study Highlights Pitfall of Large Gene Panels in Clinical Genomic Analysis

An analysis in Genetics in Medicine finds that as gene panels get larger, there is an increased chance of uncovering benign candidate variants.

Single-Cell Atlas of Drosophila Embryogenesis

A new paper in Science presents a single-cell atlas of fruit fly embryonic development over time.

Phage Cocktail Holds Promise for IBD

Researchers uncovered a combination phage therapy that targets Klebsiella pneumonia strains among individuals experiencing inflammatory bowel disease flare ups, as they report in Cell.